US Diabetes Market - Industry Analysis, Size, Growth, Trends, Outlook And Research 2017 To 2022

The US diabetes market has witnessed a rapid growth in recent years. A significant growth in the number of diabetic patients is the major factor which has contributed in influencing the demand for diabetes management products.

Request for sample report @ http://www.imarcgroup.com/request?type=report&id=688&flag=B

The latest report by IMARC Group titled, “US Diabetes Market Report: 2017 - 2022”, finds that the US diabetes market reached a value of nearly US$ 33 Billion in 2016, growing at a CAGR of more than 13% during 2009-2016. The socio-economic structure of the United States has changed dramatically over the past several years. Some of the drastic modifications the Americans have undergone include the sudden rise in the per capita income, the thriving food processing industry, and changing lifestyle patterns. These transformations have come to evolve as the root cause of the prevalence of some of the deadly diseases in the region. Diabetes is one of them, which has taken more than 27 Million patients under its sway, representing the world’s third largest patient pool in 2016. Some of the major causes of diabetes among the Americans are obesity, consumption of processed foods, stress, increasing aged-population, sedentary lifestyle, and genetic factors.

Highlights of the US diabetes market:

A huge number of diabetic patients is the biggest driving factor for the growth of the market.

Insulin represents the largest drug type, accounting for the majority of the share.

The market is expected to reach a value of around US$ 67 Billion by 2022.

The disposable incomes have, however, also helped in availing the consumers access to expensive treatments of diseases. As a result of being a region where the consumers earn and spend exceedingly, the manufacturers in the pharmaceuticals industry have secured plenty of opportunities to create and develop a market for their products. With a large number of diabetic patients, the demand for diabetes management products has increased significantly, such as insulin injection devices and insulin pumps, insulin therapies, oral and injectable diabetes drugs, blood glucose monitoring devices, etc. Owing to this growing demand, the market is further expected to reach a value of around US$ 67 Billion by 2022.

The market is segmented on the basis of drug type which includes insulin and oral anti-diabetics. Currently, insulin represents the largest market, accounting for the majority of the share. An analysis of the competitive landscape provides the details of the key players operative in the market. Some of the major players in the US diabetes market are Merck, Astra Zeneca, Novo Nordisk, and Johnson and Johnson.

Read full report with TOC @ http://www.imarcgroup.com/us-diabetes-market

The report has segmented the US diabetes market on the basis of:

Drug Type:

US Oral Antidiabetics Market
US Insulin Market

Key Players:

Merck
Astra Zeneca
Novo Nordisk
Johnson and Johnson

Browse related reports:

UK Diabetes Market @ http://www.imarcgroup.com/UK-diabetes-market

Spain Diabetes Market @ http://www.imarcgroup.com/spain-diabetes-market

About IMARC Group

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

IMARC Group

309 2nd St, Brooklyn, NY 11215, USA
Website: www.imarcgroup.com
Email: sales@imarcgroup.com
USA: +1-631-791-1145
Follow us on twitter: @imarcglobal

This release was published on openPR.